摘要
目的研究前列地尔联合常规疗法对缺血性肠病患者血清肠脂肪酸结合蛋白(IFABP)和D-二聚体(D-dimer)水平的影响。方法选取本院2015年1月至2018年3月收治的60例缺血性肠病患者,随机分为观察组与对照组,每组30例。对照组给予常规治疗,观察组在对照组的基础上给予前列地尔治疗。比较两组疗效、不良反应情况以及治疗前后血清IFABP和D-dimer水平。结果观察组治疗总有效率为93.33%,显著高于对照组的73.33%(P<0.05);治疗后,两组血清IFABP、D-dimer水平较治疗前均显著下降,且观察组治疗后明显低于对照组,差异有统计学意义(P<0.05);治疗后,观察组住院时间、便血消失时间、腹痛缓解时间、肠镜恢复时间均短于对照组(P<0.05)。两组不良反应发生率比较差异无统计学意义。结论前列地尔联合常规疗法可有效降低缺血性肠病患者血清IFABP、D-dimer水平,且安全性高,值得临床推广。
Objective To study the effect of alprostadil combined routine treatment on serum intestinal fatty acid binding protein(IFABP)and Ddimer levels in patients with ischemic bowel disease.Methods 60 patients with ischemic bowel disease admitted to the hospital from January 2015 to March 2018 were selected and randomized into observation group and control group,with 30 cases in each group.Control group was given routine treatment,and observation group was treated with alprostadil combined with routine treatment.The curative effect,adverse reactions,serum IFABP and D-dimer levels before and after treatment were compared between the two groups.Results The total effective rate of treatment in observation group(93.33%)was significantly higher than that in control group(73.33%)(P<0.05).After treatment,serum IFABP and D-dimer levels in both groups significantly decreased,and the observation group was significantly lower than those of the control group(P<0.05).After treatment,the length of hospital stay,bloody disappearance time,abdominal pain relief time and colonoscopy recovery time in observation group were shorter than those of the control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups.Conclusion Alprostadil combined routine treatment can effectively reduce serum IFABP and D-dimer levels in patients with ischemic bowel disease,and it is high safe and effective.
作者
褚毅
张景
代月
Chu Yi;Zhang Jing;Dai Yue(People's Hospital of Yuan'an County,Yichang,Hubei,444200,China)
出处
《当代医学》
2020年第18期31-33,共3页
Contemporary Medicine
关键词
前列地尔
缺血性肠病
肠脂肪酸结合蛋白
D-二聚体
Alprostadil
Ischemic bowel disease
Intestinal fatty acid binding protein
D-dimer
